Skip to content

688606.SH

Hangzhou Alltest Biotech Co., Ltd.

SSE · Healthcare · Medical - Instruments & Supplies · CN

CNY 47.64
−0.67%
Ask drillr

Year over year

Reported trailing growth

Revenue
+2.0%
EBITDA
EBIT
-42.4%
EPS
-44.1%
Free cash flow
-91.3%
Operating cash flow
-45.7%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-35.6%
EBITDA
-40.7%
EBIT
-43.5%
Net income
-42.9%
EPS
-42.9%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026